Clinical Trial: A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

U.S., Dec. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07255664) titled 'A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC' on Nov. 20.

Brief Summary: This is a First-In-Human trial investigating a novel expansion protocol of an ATIMP (CC-38), composed of autologous TIL.

Study Start Date: Nov., 2025

Study Type: INTERVENTIONAL

Condition: Metastatic Colorectal Cancer Prostate Cancer Metastatic Prostate Cancer Locally Advanced

Intervention: DRUG: CC-38

CC-38 drug product is an autologous ATIMP composed of in vitro expanded tumor-infiltrating T-lymphocytes.

DRUG: Pembrolizumab

A concomitant IMP is pembrolizumab

DRUG: ...